Skip to main content
SpringerLink
Log in

Connective Tissue Diseases

  • Chapter
Therapy of Skin Diseases

  • 1472 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gladman DD, Urowitz MB (2003) Systemic lupus erythe-matosus: clinical features. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology vol. 2. Mosby, Edinburgh, pp 1359–1379

    Google Scholar 

  2. Sontheimer RD (1999) Lupus erythematosus. In: Freedberg IM, Eisen AZ, Wolff K et al (eds) Dermatology in general medicine, vol. 2. Mcgraw-hill, New York, pp 1993–2008

    Google Scholar 

  3. Sontheimer RD, Euwer RL, Geppert TD et al (1992) Connective tissue diseases. In: Moschella SL, Hurley HJ (eds) Dermatology. WB Saunders, Philadelphia, pp 1217–1265

    Google Scholar 

  4. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6:823–835

    Article  PubMed  CAS  Google Scholar 

  5. Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564–576

    Article  PubMed  CAS  Google Scholar 

  6. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  7. Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640

    Article  PubMed  CAS  Google Scholar 

  8. Liang MH, Socher SA, Roberts WN et al (1988) Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31:817–825

    Article  PubMed  CAS  Google Scholar 

  9. Symmons DP, Coppock JS, Bacon PA et al (1988) Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 69:927–937

    PubMed  CAS  Google Scholar 

  10. Kanekura T, Yoshii N, Terasaki K et al (2003) Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 148:353–356

    Article  PubMed  CAS  Google Scholar 

  11. Goldblatt F, Isenberg DA (2005) New therapies for systemic lupus erythematosus. Clin Exp Immunol 140:205–212

    Article  PubMed  CAS  Google Scholar 

  12. Houssiau FA, Vasconcelos C, D'Cruz D et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934–3940

    Article  PubMed  Google Scholar 

  13. Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophe-nolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162

    Article  PubMed  CAS  Google Scholar 

  14. Contreras G, Pardo V, Leclercq B et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980

    Article  PubMed  CAS  Google Scholar 

  15. Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    Article  PubMed  CAS  Google Scholar 

  16. Wallace DJ (2001) Apheresis for lupus erythematosus: state of the art. Lupus 10:193–196

    Article  PubMed  CAS  Google Scholar 

  17. Anolik JH, Barnard J, Cappione A et al (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580–3590

    Article  PubMed  CAS  Google Scholar 

  18. Leandro MJ, Edwards JC, Cambridge G et al (2002) An open study of B lymphocyte depletion in systemic lupus ery-thematosus. Arthritis Rheum 46:2673–2677

    Article  PubMed  Google Scholar 

  19. Smith KG, Jones RB, Burns SM et al (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54:2970–2982

    Article  PubMed  CAS  Google Scholar 

  20. Traynor AE, Barr WG, Rosa RM et al (2002) Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 46:2917–2923

    Article  PubMed  Google Scholar 

  21. Croker JA, Kimberly RP (2005) SLE: challenges and candidates in human disease. Trends Immunol 26:580–586

    Article  PubMed  CAS  Google Scholar 

  22. Denton CP, Black C (2003) Management of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology, vol 2. Mosby, Edinburgh, pp 1493–1506

    Google Scholar 

  23. Goodfield MJD, Jones SK, Veale DJ (2004) The connective tissue diseases. In: Burns T, Breathnach S, Cox N et al (eds) Rook's textbook of dermatology, vol. 3. Blackwell, Malden, pp 56.1–56.147

    Google Scholar 

  24. Mayes MD, Reveille JD (2004) Epidemiology, demographics, and genetics. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Philadelphia, pp 39–62

    Google Scholar 

  25. Steen VD (2003) Epidemiology of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS et al (eds), Rheumatology, vol. 2. Mosby, Edinburgh, pp 1455–1462

    Google Scholar 

  26. Charles C, Clements P, Furst DE (2006) Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 367:1683–1691

    Article  PubMed  Google Scholar 

  27. Tan FK, Stivers DN, Foster MW et al (1998) Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 41:1729–1737

    Article  PubMed  CAS  Google Scholar 

  28. Tan FK, Wang N, Kuwana M et al (2001) Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 44:893–901

    Article  PubMed  CAS  Google Scholar 

  29. Guiducci S, Pignone A, Matucci-Cerinic M (2004) Raynaud's phenomenon in systemic sclerosis. In: Clements PJ, Furst DE (eds) systemic sclerosis. Williams &Wilkins, Philadelphia, pp 221–240

    Google Scholar 

  30. Ihn H (2002) Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 14:681–685

    Article  PubMed  CAS  Google Scholar 

  31. Sato S, Fujimoto M, Hasegawa M et al (2004) Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41:1123–1133

    Article  PubMed  CAS  Google Scholar 

  32. Takehara K (2003) Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 30:755–759

    PubMed  Google Scholar 

  33. Jimenez SA, Christner PJ, Gershwin ME (2004) Animal models of systemic sclerosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams &Wilkins, Philadelphia, pp 39–62

    Google Scholar 

  34. Varga J, Korn JH (2004) Emphasis on human data. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams &Wilkins, Philadelphia, pp 63–98

    Google Scholar 

  35. Hasegawa M, Hamaguchi Y, Yanaba K et al (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmu-nity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954–966

    Article  PubMed  CAS  Google Scholar 

  36. Saito E, Fujimoto M, Hasegawa M et al (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453–1462

    PubMed  CAS  Google Scholar 

  37. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the clas-sification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    Article  Google Scholar 

  38. LeRoy EC, Krieg T, Black C et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205

    PubMed  CAS  Google Scholar 

  39. Medsger TA Jr (2004) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams &Wilkins, Philadelphia, pp 17–28

    Google Scholar 

  40. Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444

    Article  PubMed  CAS  Google Scholar 

  41. Steen VD, Powell DL, Medsger TAJ (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203

    Article  PubMed  CAS  Google Scholar 

  42. Okano Y (1996) Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 22:709–735

    Article  PubMed  CAS  Google Scholar 

  43. Clements PJ, Hurwitz EL, Wong WK et al (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43:2445–2454

    Article  PubMed  CAS  Google Scholar 

  44. Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167

    PubMed  Google Scholar 

  45. Fries R, Shariat K, von Wilmowsky H et al (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vaso-dilatory therapy. Circulation 112:2980–2985

    PubMed  CAS  Google Scholar 

  46. Korn JH, Mayes M, Matucci Cerinic M et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–9393

    Article  PubMed  CAS  Google Scholar 

  47. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with sclero-derma-associated lung fibrosis and the raynaud phenomenon. Ann Intern Med 139:871–873

    PubMed  Google Scholar 

  48. Rubin LJ, Badesch DB, Barst RJ et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903

    Article  PubMed  CAS  Google Scholar 

  49. Steen VD (2004) Renal involvement in systemic sclerosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams &Wilkins, Philadelphia, pp 279–292

    Google Scholar 

  50. Lopez-Ovejero JA, Saal SD, D'Angelo WA et al (1979) Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 300:1417–1419

    Article  PubMed  CAS  Google Scholar 

  51. Clements P, Lachenbrush P, Seibold J et al (1995) Inter and intraobserver variability of total skin thickness score (modi-fied Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281–1285

    PubMed  CAS  Google Scholar 

  52. Pope JE, Bellamy N, Seibold JR et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351–1358

    Article  PubMed  CAS  Google Scholar 

  53. van den Hoogen FH, Boerbooms AM, Swaak AJ et al (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35:364–372

    Article  PubMed  Google Scholar 

  54. Clements PJ, Lachenbruch PA, Sterz M et al (1993) Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36:75–83

    Article  PubMed  CAS  Google Scholar 

  55. Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970

    Article  PubMed  CAS  Google Scholar 

  56. Khanna D, Clements PJ, Furst DE et al (2005) Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveoli-tis: results from the Scleroderma Lung Study. Arthritis Rheum 52:592–600

    Article  PubMed  Google Scholar 

  57. Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  PubMed  CAS  Google Scholar 

  58. Furst DE, Nash R, Sullivan KM et al (2004) High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward. J Rheumatol 31:2331–2335

    PubMed  Google Scholar 

  59. Denton CP, Black CM (2005) Targeted therapy comes of age in scleroderma. Trends Immunol 26:596–602

    Article  PubMed  CAS  Google Scholar 

  60. Varga J (2004) Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts? Curr Rheumatol Rep 6:164–170

    Article  PubMed  Google Scholar 

  61. Denton CP, Merkel PA, Furst DE et al (2004) Anti-TGF beta 1 therapy for diffuse cutaneous systemic sclerosis: a multicenter, randomized, placebo-controlled PhaseI/II trial of CAT-192. Arthritis Rheum 50:S691–S692

    Google Scholar 

  62. Ishida W, Bhattacharyya S, Hinchcliff M et al (2006) Novel role of C-abl tyrosine kinase in profibrotic TGF-beta responses: selective moduration by the anticancer drug ima-tinib methylate (gleevec). Arthritis Rheum 54:S776–S777

    Google Scholar 

  63. Lafyatis R, Kissin E, Viger K et al (2006) Rituximab treatment for patients with diffuse cutaneous systemic sclerosis-A phase I study. Arthritis Rheum 54:S523–S524

    Article  Google Scholar 

  64. Oddies CV, Medsger TA Jr (2003) Inflammatory muscle disease:clinical features. In: Hochberg MC, Silman AJ, Smolen JS (eds) Rheumatology, vol. 2. Mosby, Edinburgh, pp 1537–1554

    Google Scholar 

  65. Sontheimer RD (1999) Dermatomyositis. In: Freedberg IM, Eisen AZ, Wolff K et al (eds) Dermatology in general medicine, vol 2. McGraw-Hill, New York, pp 2009–2022

    Google Scholar 

  66. Arnett FC, Goldstein R, Duvic M et al (1988) Major histo-compatibility complex genes in systemic lupus erythemato-sus, Sjogren's syndrome, and polymyositis. Am J Med 85:38–41

    Article  PubMed  CAS  Google Scholar 

  67. Christopher-Stine L, Plotz PH (2004) Myositis: an update on pathogenesis. Curr Opin Rheumatol 16:700–706

    Article  PubMed  CAS  Google Scholar 

  68. Love LA, Leff RL, Fraser DD et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360–374

    CAS  Google Scholar 

  69. Christensen ML, Pachman LM, Schneiderman R et al (1986) Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 29:1365–1370

    Article  PubMed  CAS  Google Scholar 

  70. Medsger TA Jr, Dawson WN Jr, Masi AT (1970) The epidemiology of polymyositis. Am J Med 48:715–723

    Article  PubMed  Google Scholar 

  71. Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNA syn-thetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26:459–467

    Article  PubMed  CAS  Google Scholar 

  72. Bohan A, Peter JB (1975) Polymyositis and dermatomyosi-tis (first of two parts). N Eng J Med 292:344–348

    Article  CAS  Google Scholar 

  73. Bohan A, Peter JB (1975) Polymyositis and dermatomyosi-tis (second of two parts). N Eng J Med 292:403–407

    Article  CAS  Google Scholar 

  74. Euwer RL, Sontheimer RD (1991) Amyopathic dermato-myositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 24:959–966

    Article  PubMed  CAS  Google Scholar 

  75. Gerami P, Schope JM, McDonald L et al (2006) A systematic review of adult-onset clinically amyopathic dermato-myositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54:597–613

    Article  PubMed  Google Scholar 

  76. Euwer RL, Sontheimer RD (1994) Dermatologic aspects of myositis. Curr Opin Rheumatol 6:583–589

    Article  PubMed  CAS  Google Scholar 

  77. Clawson K, Oddis CV (1995) Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 38:1519–1523

    Article  PubMed  CAS  Google Scholar 

  78. Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576

    Article  PubMed  CAS  Google Scholar 

  79. Roberts LJ, Fink CW (1988) Childhood polymyositis/der-matomyositis. Clin Dermatol 6(36–46):49–51

    Google Scholar 

  80. Kaji K, Fujimoto M, Hasegawa M et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46:25–28

    Article  CAS  Google Scholar 

  81. Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000

    Article  PubMed  CAS  Google Scholar 

  82. Berger RG, Featherstone GL, Raasch RH et al (1987) Treatment of calcinosis universalis with low-dose warfarin. Am J Med 83:72–76

    Article  PubMed  CAS  Google Scholar 

  83. Oliveri MB, Palermo R, Mautalen C et al (1996) Regression of calcinosis during diltiazem treatment in juvenile dermato-myositis. J Rheumatol 23:2152–2155

    PubMed  CAS  Google Scholar 

  84. Wilkes MR, Sereika SM, Fertig N et al (2005) Treatment of antisynthetase-associated interstitial lung disease with tac-rolimus. Arthritis Rheum 52:2439–2446

    Article  PubMed  CAS  Google Scholar 

  85. Pisoni CN, Cuadrado MJ, Khamashta MA et al (2007) Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46:516–518

    Article  CAS  Google Scholar 

  86. Levine TD (2005) Rituximab in the treatment of dermatomy-ositis: an open-label pilot study. Arthritis Rheum 52:601–607

    Article  PubMed  CAS  Google Scholar 

  87. Mandell BF, Hoffman GS (1999) Systemic necrotizing arteritis. In: Freedberg IM, Eisen AZ, Wolff K et al (eds) Dermtology in general medicine. McGraw-Hill, New York, pp 2034–2044

    Google Scholar 

  88. Soto O, Conn DL (2003) Polyarteritis nodosa and microscopic polyangiitis. In: Hochberg MC, Silman AJ, Smolen JS (eds) Rheumatology, vol 2. Mosby, Edinburgh, pp 1611–1621

    Google Scholar 

  89. Xiao H, Heeringa P, Hu P et al (2002) Antineutrophil cyto-plasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955–963

    PubMed  CAS  Google Scholar 

  90. Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192

    Article  PubMed  CAS  Google Scholar 

  91. Gayraud M, Guillevin L, le Toumelin P et al (2001) Longterm followup of polyarteritis nodosa, microscopic poly-angiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675

    Article  PubMed  CAS  Google Scholar 

  92. Guillevin L, Cohen P, Mahr A et al (2003) Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorti-coids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49:93–100

    Article  PubMed  CAS  Google Scholar 

  93. Gordon M, Luqmani RA, Adu D et al (1993) Relapses in patients with a systemic vasculitis. Q J Med 86:779–789

    PubMed  CAS  Google Scholar 

  94. Specks U (2005) Methotrexate for Wegener's granulomato-sis: what is the evidence? Arthritis Rheum 52:2237–2242

    Article  PubMed  CAS  Google Scholar 

  95. Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44

    Article  PubMed  CAS  Google Scholar 

  96. Jayne DR, Chapel H, Adu D et al (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439

    Article  PubMed  CAS  Google Scholar 

  97. Daikeler T, Kotter I, Bocelli Tyndall C et al (2006) Haematopoietic stem cell transplantation for vasculitis including Behcet;s disease and polychondritis—a retrospective analysis of patients recorded to the European Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) databases and a review of the literature. Ann Rheum Dis 66:202–207

    Article  PubMed  Google Scholar 

  98. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352:351–361

    Article  Google Scholar 

  99. Catoggio LJ (2003) Inflammatory muscle disease: management. In: Hochberg MC, Silman AJ, Smolen JS, Weinblattt ME, Weisman MH (eds) Rheumatology, vol 2. Mosby, Edinburgh, pp 1555–1562

    Google Scholar 

  100. Targoff IN, Mamyrova G, Trieu EP et al (2006) A novel autoantibody to a 155-kd protein is associated with der-matomyositis. Arthritis Rheum 54:3682–3689

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan

    Minoru Hasegawa

  2. Department of Dermatology, Nagasaki University, Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

    Shinichi Sato

Authors
  1. Minoru Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minoru Hasegawa .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik und Poliklinik für Dermatologie und Venerologie, Kerpener Str. 62, Köln, 50924, Germany

    Thomas Krieg

  2. Dept. Dermatology, Columbia University Medical Center, 12th Floor, Herbert Irving Pavilion 161 Fort Washington Ave, New York, NY, 10032, USA

    David R. Bickers

  3. Dept. Dermatology & Cutaneous Sciences, Kyoto University Graduate School of Medicine, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

    Yoshiki Miyachi

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hasegawa, M., Sato, S. (2010). Connective Tissue Diseases. In: Krieg, T., Bickers, D.R., Miyachi, Y. (eds) Therapy of Skin Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78814-0_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-78814-0_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-78813-3

  • Online ISBN: 978-3-540-78814-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation